Browse the evidence

A biomimetic and comparative approach can provide insights into human ageing processes.

Practitioners should consider integrating insights from diverse species to enhance understanding of ageing.

There is a need for renewed focus in the pathophysiology of ageing and age-related disease.

Researchers should explore new avenues in the study of ageing and related diseases.

Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the global population.

Healthcare providers should be aware of the high prevalence of NAFLD in their patient populations.

The most common adverse events associated with semaglutide are gastrointestinal in nature.

Healthcare providers should inform patients about potential gastrointestinal side effects when prescribing semaglutide.

Ex-DARPin fusion proteins significantly improved the survival of pancreatic islets in diabetic mice.

Improving pancreatic islet survival could enhance insulin production and overall diabetes management.

Patients with coronary artery disease (CAD) have a lower capillary-to-fiber ratio (C/Fi) and capillary-to-fiber perimeter exchange (CFPE) index in Type II fibers compared to healthy controls.

Understanding these differences can inform targeted rehabilitation strategies for CAD patients.

There is a complex and bidirectional relationship between adipose and breast tissues.

Understanding this relationship can help in developing targeted interventions for breast cancer.

Increases in inflammatory markers from training do not correlate with any outcome variable.

Training-induced inflammation does not impact performance outcomes.

Recent innovations in obesity diagnosis include bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, alongside emerging biomarkers from 'omics' technologies.

Healthcare practitioners should consider incorporating BIA and DXA scans for more accurate obesity diagnosis.

The pathogenesis of obesity-related glomerulopathy is complex, involving multiple factors.

Recognizing the complexity of ORG can guide more targeted therapeutic approaches.

The internet-based marketing of plant-based formulations for enhancing metabolism has surged.

Practitioners should be aware of the growing trend in plant-based metabolism enhancers in the market.

GIP(1-30)NH2 and GIP(1-42) have similar effects on human pancreatic islets.

Both GIP variants can be expected to have similar effects on insulin and glucagon secretion in pancreatic islets.

The SDOC definition has high discriminatory accuracy for identifying ADL disability.

The SDOC criteria can be effectively used to assess risk of ADL disability in older adults.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

18F-FDG PET scanning is the most commonly used imaging modality to detect and quantify human BAT activity in vivo.

Clinicians can utilize 18F-FDG PET for assessing BAT activity in patients.

Tissue concentrations and mRNA expression of GLP-1 and PYY do not differ between individuals with obesity and lean controls.

This indicates that obesity does not alter the local production of GLP-1 and PYY in the gut.

GLP-1 RA therapy was associated with a low rate of major adverse events in LVAD patients.

GLP-1 RA appears to be a safe adjunct therapy for LVAD patients.

GLP-1 RA therapy was not associated with increased incidence of GI cancers.

GLP-1 RAs may be a safer option regarding GI cancer risk for patients with type 2 diabetes.

No significant differences were observed in biliary cancer or hepatocellular carcinoma between GLP-1 RAs and other oral antidiabetic medications.

Clinicians can consider GLP-1 RAs without increased concern for biliary or liver cancer risks.

Both drugs are associated with kidney and thyroid disorders.

Healthcare providers should monitor kidney and thyroid function in patients using these medications.

Natural products from plants are a promising source for new lead structures for drug discovery targeting obesity.

Practitioners may consider exploring natural plant metabolites for obesity treatment.

JMV-449 induced noticeable dose-dependent insulin-releasing actions in BRIN-BD11 beta-cells.

JMV-449 may be a promising agent for enhancing insulin secretion in diabetes treatment.

A new classification of patients with diabetes mellitus into clusters can assess the risk of developing diabetic nephropathy.

Practitioners can use this classification to better assess nephropathy risk in diabetic patients.

Systematic screening for advanced fibrosis related to MASLD is recommended for patients with T2D.

Healthcare professionals should implement systematic screening for liver fibrosis in diabetic patients.